You are here: Industry Insights > Market News > Virafin from Zydus Cadila priced at Rs 11,995 per dose

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Virafin from Zydus Cadila priced at Rs 11,995 per dose

expresspharmaMay 12, 2021

Tag: Zydus Cadila , Virafin , COVID-19 , DCGI

Favorites

As per reports, Zydus Cadila has fixed the price of Virafin, a medicine that has received EUA for COVID-19 treatment, at Rs 11,995 per dose. Reportedly, the company has commenced dispatching the drug which can reportedly reduce oxygen support in COVID-19 patients.

Virafin from Zydus Cadila priced at Rs 11,995 per dose

The Drug Controller General of India (DCGI) gave emergency authorisation for restricted use to Virafin, a single-use therapy, on April 23.

Technically known as Pegylated Interferon alpha-2b, it is used to treat moderate infection of COVID-19. The company has said, “91.15 per cent of patients treated with PegIFN were RT-PCR negative by day 7.”

Previous:Woodstock Sterile Solutions Names Oliver Vogt as VP and General Manager

Next:Kejriwal asks PM to share vaccine formula with pharma firms to ramp up manufacturing

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Virafin from Zydus Cadila priced at Rs 11,995 per dose | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Virafin from Zydus Cadila priced at Rs 11,995 per dose

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Virafin from Zydus Cadila priced at Rs 11,995 per dose

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>